Improve your sales insight using AI
Will 2019 be the year in which pharma sales and marketing teams use augmented intelligence to successfully exploit infinite data? Buzz Lightyear made his first...
The impact of Brexit on the regulatory and marketing landscape
Brexit-related change will define the European pharmaceutical and healthcare sector in 2019, both in terms of how drug products are regulated and how they...
HFMA’s Chris Calkin on how the money in the NHS system works
How does the money flow through the NHS? Here’s the inside intelligence.
The complicated structure of the NHS is often impenetrable, even to those who...
New standards launched to improve public involvement in research
New national standards to improve the quality of public involvement in research.
Old sales techniques are history and sales forces must adapt
Despite all the rhetoric about multichannel marketing, patient centricity and the inexorable rise of digital, the most effective sales channel is still standing ‘two...
How to concentrate sales efforts in the right place
Right place, right time In part two of a series looking at the effective use of data, Dr Graham Leask addresses how to concentrate sales...
Sales force awakens to boost ROI
Sales force awakens
Karen Bell, Director of Business Development at Ashfield Commercial and Clinical UK, on maximising return on investment. Sales force effectiveness (SFE) is about...
The rise of digital marketing: pharma and social media
Social media is a prerequisite for most businesses, but how has the historically reticent pharma industry been adapting?
Graeme Smith
Managing Partner, Fortis Pharma Consulting
The highly–regulated...
Marketing Focus: the shift from treatment to prevention
Read part one of Setting the scene in the June edition of Pf Magazine here. PART TWO: Setting the scene
Dr Graham Leask and Stewart Adkins...
Marketing Focus: helping modern marketeers to thrive
PART ONE: Setting the scene Introducing a new series of ‘Marketing Focus’ articles, helping modern marketeers to thrive in the changing healthcare environment. In the first...
Latest articles
What’s been authorised? UK, Europe, US drug approvals
Pf summarises the UK, Europe and US drug approvals from 20 - 24 Jan 2020. UK The National Institute for Health and Care Excellence published draft...
Digital interventions for behaviour change
New NICE guidance looks at digital interventions for behaviour change and suggests that these interventions such as apps, wearable devices and online programmes and...
Acute aortic dissection is a ‘ticking time bomb’
Safety body calls for earlier recognition of ‘ticking time bomb’ aortic dissection to prevent deaths as its new report reveals that up to half...
Popular articles
What’s been authorised? UK, Europe, US drug approvals
Pf summarises the UK, Europe and US drug approvals from 20 - 24 Jan 2020. UK The National Institute for Health and Care Excellence published draft...
Key publications to impact the UK access environment in 2020
Craig Bradley, Commercial Lead Rare GI at Takeda, PM Society Chair & PM Society Market Access Interest Group Lead, looks at key publications to...
AstraZeneca’s Tagrisso▼ (osimertinib) rejected by NICE for use in NHS England
The National Institute for Health and Care Excellence (NICE) has published final guidance that does not recommend AstraZeneca's Tagrisso▼ (osimertinib) for use within NHS...
NICE rejects Janssen’s Stelara for moderate to severe ulcerative colitis
The National Institute for Health and Care Excellence (NICE) has not recommended ustekinumab, Janssen's Stelara, for treating moderately to severely active ulcerative colitis in...
Tiofarma admits illegal role in fludrocortisone anti-competitive agreement
Tiofarma has admitted that it took part in a fludrocortisone anti-competitive agreement that resulted in significant price hikes for the essential medicine. This means that...